| Name | Title | Contact Details |
|---|
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
Evolent Health supports progressive health care systems lead, build and own the path to value-based care. Headquartered in Arlington, Virginia, we are backed by: The Advisory Board Company (NASDAQ: ABCO), University of Pittsburgh Medical Center Health Plan, and TPG Growth. We integrate the people, processes and technology needed to advance value-based care delivery and innovative payment models.
Advanced Imaging is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens® Contact Hearing Solution, which directly vibrates the eardrum with a tiny lens in order to activate the natural hearing process. This revolutionary, nonsurgical hearing solution delivers the broadest bandwidth available today and superior sound quality. The Earlens® Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. We believe that people with hearing loss shouldn`t have to think about their hearing in everyday situations. Earlens was designed specifically to address the sound quality and speech understanding complaints that are common among hearing aid wearers and contribute to non-compliance. We make every Earlens device custom-fit for each patient`s unique anatomy and hearing needs, while offering modern features such as Bluetooth streaming.
Ulthera is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.